The saga of the ALS treatment Relyvrio may be generating ripple effects across the disease landscape.
Key Takeaways
-
NeuroSense is adjusting its Phase III trial design in part because of Relyvrio's failure.
Alon Ben-Noon, CEO of NeuroSense Therapeutics Ltd., which is developing PrimeC as an amyotrophic lateral sclerosis treatment, said the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?